181 related articles for article (PubMed ID: 21784778)
1. Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus.
Pinto LF; Velásquez CJ; Prieto C; Mestra L; Forero E; Márquez JD
Lupus; 2011 Oct; 20(11):1219-26. PubMed ID: 21784778
[TBL] [Abstract][Full Text] [Related]
2. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Baldovino S; Menegatti E; La Grotta R; Modena V
Nephrol Dial Transplant; 2011 Dec; 26(12):3987-92. PubMed ID: 21385860
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
Terrier B; Amoura Z; Ravaud P; Hachulla E; Jouenne R; Combe B; Bonnet C; Cacoub P; Cantagrel A; de Bandt M; Fain O; Fautrel B; Gaudin P; Godeau B; Harlé JR; Hot A; Kahn JE; Lambotte O; Larroche C; Léone J; Meyer O; Pallot-Prades B; Pertuiset E; Quartier P; Schaerverbeke T; Sibilia J; Somogyi A; Soubrier M; Vignon E; Bader-Meunier B; Mariette X; Gottenberg JE;
Arthritis Rheum; 2010 Aug; 62(8):2458-66. PubMed ID: 20506527
[TBL] [Abstract][Full Text] [Related]
4. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
Jovancevic B; Lindholm C; Pullerits R
Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.
Garcia-Carrasco M; Mendoza-Pinto C; Sandoval-Cruz M; Soto-Vega E; Beltran-Castillo A; Jimenez-Hernandez M; Graillet D; Gonzalez L; Rojas-Rodriguez J; Pineda-Almazana A; Zamudio-Huerta L; Lopez-Colombo A
Lupus; 2010 Feb; 19(2):213-9. PubMed ID: 19965944
[TBL] [Abstract][Full Text] [Related]
6. Pediatric systemic lupus erythematosus in Thammasat University Hospital.
Pusongchai T; Jungthirapanich J; Khositseth S
J Med Assoc Thai; 2010 Dec; 93 Suppl 7():S283-93. PubMed ID: 21294427
[TBL] [Abstract][Full Text] [Related]
7. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G
Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
[TBL] [Abstract][Full Text] [Related]
8. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
[TBL] [Abstract][Full Text] [Related]
9. Effects of rituximab on resistant SLE disease including lung involvement.
Reynolds JA; Toescu V; Yee CS; Prabu A; Situnayake D; Gordon C
Lupus; 2009 Jan; 18(1):67-73. PubMed ID: 19074171
[TBL] [Abstract][Full Text] [Related]
10. [Long-term follow-up of patients with refractory systemic lupus erythematosus during rituximab treatment].
Tsanian MÉ; Solov'ev SK; Torgashina AV; Aleksandrova EN; Radenska-Lopovok SG; Nikolaeva EV; Khrennikova IaB; Nasonov EL
Ter Arkh; 2014; 86(5):40-9. PubMed ID: 25026801
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice.
Ogawa H; Kameda H; Amano K; Takeuchi T
Lupus; 2010 Feb; 19(2):162-9. PubMed ID: 19952069
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response.
Jónsdóttir T; Zickert A; Sundelin B; Henriksson EW; van Vollenhoven RF; Gunnarsson I
Rheumatology (Oxford); 2013 May; 52(5):847-55. PubMed ID: 23287364
[TBL] [Abstract][Full Text] [Related]
13. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study.
Fernández-Nebro A; de la Fuente JL; Carreño L; Izquierdo MG; Tomero E; Rúa-Figueroa I; Hernández-Cruz BE; Narváez J; Ucar E; Olivé A; Zea A; Fernández-Castro M; Raya-Álvarez E; Pego-Reigosa JM; Freire M; Martínez-Taboada VM; Pérez-Venegas J; Sánchez-Atrio AI; Villa-Blanco I; Manrique-Arija S; López-Longo FJ; Carreira PE; Martínez-Pérez R; García-Vicuña R
Lupus; 2012 Sep; 21(10):1063-76. PubMed ID: 22786985
[TBL] [Abstract][Full Text] [Related]
14. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations.
Holle JU; Dubrau C; Herlyn K; Heller M; Ambrosch P; Noelle B; Reinhold-Keller E; Gross WL
Ann Rheum Dis; 2012 Mar; 71(3):327-33. PubMed ID: 22021864
[TBL] [Abstract][Full Text] [Related]
15. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence.
Narváez J; Ríos-Rodriguez V; de la Fuente D; Estrada P; López-Vives L; Gómez-Vaquero C; Nolla JM
Semin Arthritis Rheum; 2011 Dec; 41(3):364-72. PubMed ID: 21875742
[TBL] [Abstract][Full Text] [Related]
16. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
Smith KG; Jones RB; Burns SM; Jayne DR
Arthritis Rheum; 2006 Sep; 54(9):2970-82. PubMed ID: 16947528
[TBL] [Abstract][Full Text] [Related]
17. Lupus nephritis: prolonged immunoadsorption (IAS) reduces proteinuria and stabilizes global disease activity.
Stummvoll GH; Schmaldienst S; Smolen JS; Derfler K; Biesenbach P
Nephrol Dial Transplant; 2012 Feb; 27(2):618-26. PubMed ID: 21617196
[TBL] [Abstract][Full Text] [Related]
18. [Synchronizing therapy with plasmapheresis and cyclophosphamide in rapidly progressing systemic lupus erythematosis with kidney involvement].
Demin AA; Sentiakova TN; Smirnov VV; Demina LM; Mamin IV
Ter Arkh; 1996; 68(5):27-30. PubMed ID: 9082593
[TBL] [Abstract][Full Text] [Related]
19. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
Lu TY; Ng KP; Cambridge G; Leandro MJ; Edwards JC; Ehrenstein M; Isenberg DA
Arthritis Rheum; 2009 Apr; 61(4):482-7. PubMed ID: 19333973
[TBL] [Abstract][Full Text] [Related]
20. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]